CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
快速递送保留初始和干性表型的下一代 CAR-T 细胞以治疗侵袭性淋巴瘤
英文原题：Express Delivery of Next-Generation CAR T Cells with Preserved Naive and Stemness Phenotypes for the Treatment of Aggressive Lymphomas.
查看英文原题
Express Delivery of Next-Generation CAR T Cells with Preserved Naive and Stemness Phenotypes for the Treatment of Aggressive Lymphomas.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
在本期《Cancer Discovery》中，Dickinson 及其同事报告了 YTB323 首次人体研究的临床数据。YTB323 是一种新型自体靶向 CD19 的CAR-T 细胞疗法，利用 T-Charge 平台制备，并保留初始 T 细胞状态和干性表型。YTB323 治疗取得较高总体缓解率、持久的完全缓解，且总体安全性良好。其细胞剂量最高可比 tisagenlecleucel 低 25 倍。相关研究见 Dickinson 等人，第 1982 页（10）。
展开英文摘要原文
In this issue of Cancer Discovery, Dickinson and colleagues present clinical data from a first-in-human study of YTB323, a novel autologous CD19-directed chimeric antigen receptor T-cell therapy generated on the T-Charge platform with preserved naive state and stemness phenotypes. Treatment with YTB323 achieved high overall response rates, durable complete remissions, and good overall safety. Their cell doses are up to 25-fold lower than with tisagenlecleucel. See related article by Dickinson et al., p. 1982 (10).
论文信息
- 作者
- Wang M
- 单位
- The University of Texas MD Anderson Cancer Center, Houston, Texas.United States
- 文献类型
- 社论 · 非美国政府资助研究 · 评论
- 期刊
- Cancer discovery2023 Sep 6
- 原文标识
- PubMed 37671474 · DOI 10.1158/2159-8290.CD-23-0735